Recent Updates — AMRN

Amarin Corporation plc reported a net income of $0.2 million for the third quarter ended September 30, 2026, marking its first profitable quarter in over two years. Total net revenue declined 20% to $39.6 million from $49.7 million in the prior-year period, driven by a 30% drop in U.S. VASCEPA sales due to generic competition and lower European licensing purchases. Operating expenses fell 44% to $18.5 million following completed restructuring initiatives. The company generated $9.2 million in net cash from operating activities and ended the quarter with $323.4 million in cash, remaining debt-free. Amarin Corporation plc develops and commercializes cardiovascular therapies, primarily VASCEPA.

Amarin Corporation plc reported financial results for the second quarter and first half of 2026. Total net revenue declined to $42.2 million from $72.7 million in Q2 2025, primarily due to a $25 million upfront payment received in the prior year period associated with its exclusive license agreement with Recordati S.p.A. for European commercialization. Operating expenses decreased by 59% to $27.0 million as the company completed its $70 million annual cost savings initiative. The company reported a net loss of $7.7 million, compared to $14.1 million in Q2 2025, and maintained a cash position of $314.6 million while remaining debt-free. In-market demand for VASCEPA/VAZKEPA grew 59% year-over-year across its global partner network, with European demand rising 69%. Amarin operates in the pharmaceutical industry, developing and commercializing cardiovascular treatments.